497 related articles for article (PubMed ID: 27876314)
1. Risk of Jaw Osteonecrosis After Intravenous Bisphosphonates in Cancer Patients and Patients Without Cancer.
Goodwin JS; Zhou J; Kuo YF; Baillargeon J
Mayo Clin Proc; 2017 Jan; 92(1):106-113. PubMed ID: 27876314
[TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonates.
Baillargeon J; Kuo YF; Lin YL; Wilkinson GS; Goodwin JS
Ann Pharmacother; 2011 Oct; 45(10):1199-206. PubMed ID: 21954448
[TBL] [Abstract][Full Text] [Related]
3. The national-scale cohort study on bisphosphonate-related osteonecrosis of the jaw in Taiwan.
Yuh DY; Chang TH; Huang RY; Chien WC; Lin FG; Fu E
J Dent; 2014 Oct; 42(10):1343-52. PubMed ID: 24907558
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons.
Khan AA; Rios LP; Sándor GK; Khan N; Peters E; Rahman MO; Clokie CM; Dore E; Dubois S
J Rheumatol; 2011 Jul; 38(7):1396-402. PubMed ID: 21498483
[TBL] [Abstract][Full Text] [Related]
5. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
6. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?
Otto S; Tröltzsch M; Jambrovic V; Panya S; Probst F; Ristow O; Ehrenfeld M; Pautke C
J Craniomaxillofac Surg; 2015 Jul; 43(6):847-54. PubMed ID: 25958767
[TBL] [Abstract][Full Text] [Related]
7. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
[TBL] [Abstract][Full Text] [Related]
8. External auditory canal and middle ear cholesteatoma and osteonecrosis in bisphosphonate-treated osteoporosis patients: a Danish national register-based cohort study and literature review.
Thorsteinsson AL; Vestergaard P; Eiken P
Osteoporos Int; 2014 Jul; 25(7):1937-44. PubMed ID: 24664275
[TBL] [Abstract][Full Text] [Related]
9. Medication-related osteonecrosis of the jaws from once per year intravenous zoledronic acid (Reclast): report of 4 cases.
Lee CY; Suzuki JB
Implant Dent; 2015 Apr; 24(2):227-31. PubMed ID: 25734948
[TBL] [Abstract][Full Text] [Related]
10. Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S.
Skrepnek GH; Seal B; Tangirala M; Jeffcoat MK; Watts NB; Hay JW
Gen Dent; 2010; 58(6):484-92; quiz 493-4. PubMed ID: 21062718
[TBL] [Abstract][Full Text] [Related]
11. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis.
Tennis P; Rothman KJ; Bohn RL; Tan H; Zavras A; Laskarides C; Calingaert B; Anthony MS
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):810-7. PubMed ID: 22711458
[TBL] [Abstract][Full Text] [Related]
12. Involvement of the maxillary sinus in bisphosphonate-related osteonecrosis of the jaw: Radiologic aspects.
Wasserzug O; Kaffe I; Lazarovici TS; Weissman T; Yahalom R; Fliss DM; Yarom N
Am J Rhinol Allergy; 2017 Jan; 31(1):36-39. PubMed ID: 28234151
[TBL] [Abstract][Full Text] [Related]
13. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan.
Liu FC; Luk KC; Chen YC
Osteoporos Int; 2023 Oct; 34(10):1729-1737. PubMed ID: 37326685
[TBL] [Abstract][Full Text] [Related]
14. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis.
Wilkinson GS; Kuo YF; Freeman JL; Goodwin JS
J Natl Cancer Inst; 2007 Jul; 99(13):1016-24. PubMed ID: 17596574
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes.
O'Ryan FS; Lo JC
J Oral Maxillofac Surg; 2012 Aug; 70(8):1844-53. PubMed ID: 22595135
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate-related osteonecrosis of the jaws.
Kushner GM; Alpert B
Curr Opin Otolaryngol Head Neck Surg; 2011 Aug; 19(4):302-6. PubMed ID: 21677585
[TBL] [Abstract][Full Text] [Related]
17. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the prognosis of bisphosphonate-related osteonecrosis of the jaw caused by oral and intravenous bisphosphonates.
Shintani T; Hayashido Y; Mukasa H; Akagi E; Hoshino M; Ishida Y; Hamana T; Okamoto K; Kanda T; Koizumi K; Yoshioka Y; Tani R; Toratani S; Okamoto T
Int J Oral Maxillofac Surg; 2015 Jul; 44(7):840-4. PubMed ID: 25861974
[TBL] [Abstract][Full Text] [Related]
19. Safety of bisphosphonates.
Orozco C; Maalouf NM
Rheum Dis Clin North Am; 2012 Nov; 38(4):681-705. PubMed ID: 23137577
[TBL] [Abstract][Full Text] [Related]
20. Osteonecrosis of the jaw after oral bisphosphonate for osteoporosis.
Tong CK; Ho ST; Wong SL
Hong Kong Med J; 2010 Apr; 16(2):145-8. PubMed ID: 20354251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
